- Supported exchanges /
- LSE /
- 0QCO.LSE
Pharming Group N.V. (0QCO LSE) stock market data APIs
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Pharming Group N.V. Financial Data Overview
| 0.7108 | |
| 0.7108 | |
| - | |
| 0.7621 | |
| 0.7108 | |
| 0.65-1.312 | |
| 501 M | |
| 0.5363 | |
| 639 M | |
| 278 M | |
| -0.0016 | |
| 0.842 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Pharming Group N.V. Fundamental Data is available in our Financial Data APIs
- Net Revenue 278 M
- EBITDA -5 037 000
- Earnings Per Share 0.015
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Pharming Group N.V. Earnings via APIs
- Latest Release 2024-08-01
- EPS/Forecast NaN
Get Pharming Group N.V. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
